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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYDisrupted IKAROS activity is a recurrent feature of some human leukemias, but effects on normal human hematopoietic cells are largely
unknown. Here, we used lentivirally mediated expression of a dominant-negative isoform of IKAROS (IK6) to block normal IKAROS
activity in primitive human cord blood cells and their progeny. This produced amarked (10-fold) increase in serially transplantablemulti-
potent IK6+ cells as well as increased outputs of normally differentiating B cells and granulocytes in transplanted immunodeficient mice,
without producing leukemia. Accompanying T/natural killer (NK) cell outputswere unaltered, and erythroid and platelet productionwas
reduced. Mechanistically, IK6 specifically increased human granulopoietic progenitor sensitivity to two growth factors and activated
CREB and its targets (c-FOS and Cyclin B1). In more primitive human cells, IK6 prematurely initiated a B cell transcriptional program
without affecting the hematopoietic stem cell-associated gene expression profile. Some of these effects were species specific, thus iden-
tifying novel roles of IKAROS in regulating normal human hematopoietic cells.INTRODUCTION
The IKAROS transcription factor is essential for normal
mouse lymphopoiesis, and its suppression by dominant-
negative isoforms produces T cell tumors (Payne and
Dovat, 2011). In human cells, the IK6 dominant-negative
isoform has been reported to inhibit erythroid and B cell
production (Dijon et al., 2008; Tonnelle et al., 2001; Ton-
nelle et al., 2009) and to produce an acute leukemia in
cord blood cells cotransduced with a virus encoding
BCR-ABL1 (Theocharides et al., 2014). A greater under-
standing of the role of IKAROS in the human blood sys-
tem is of particular interest given the high frequency of
inactivating mutations in IKZF1 (encoding IKAROS) in
human B cell leukemias as well as occasional myeloid
malignancies (Grossmann et al., 2011; Ja¨ger et al., 2010;
Mullighan et al., 2008; Nacheva et al., 2013; Nakayama
et al., 1999).
Here, we show that lentiviral-mediated expression of IK6
has different effects on primitive mouse and human
hematopoietic cells. In mice, B-lineage outputs were sup-
pressed and myeloid and T cells were increased, culmi-
nating occasionally in T cell leukemia. In contrast, we
find that primitive human cord blood (CB) cells transduced
with the same vector produce increased numbers of
myeloid and B-lineage cells as well as cells able to repopu-
late secondary recipient mice for more than 7 months
but show neither a change in T cell output nor any evi-
dence of leukemogenesis. Together, these findings point
to an ability of IKAROS to regulate primitive stages of hu-
man hematopoiesis.Stem Cell RRESULTS
Construction and Validation of an IK6 Lentiviral
Vector
To analyze the effects of disrupting IKAROS activity in he-
matopoietic cells, we created two similarly high-titer lenti-
virus preparations: one encoding GFP plus IK6 (lacking all
four DNA-binding motifs but retaining the IKAROS pro-
tein-protein interaction domain; Figure 1A), and another
control virus encoding yellow fluorescent protein (YFP)
only. We then transduced separate aliquots of lineage
SCA-1+KIT+ (LSK) adult mouse bone marrow (BM) cells
with each virus and cotransplanted paired aliquots of
these cells without further selection (1.5 3 104 of each/
recipient) into four congenic B6-W41/W41 (W41) and
four allogeneic nonobese diabetic/severe combined im-
munodeficiency (NOD/SCID) interleukin-2 receptor, g
chain null (NSG) mice. Both types of recipient showed
enhanced T cell and granulocyte-macrophage/monocyte
(GM) outputs but transiently suppressed B cell outputs
from the IK6-transduced cells (Figures S1A–S1C available
online). After 24 weeks, all BM cells harvested from each
primary NSG mouse were transplanted into two second-
ary NSG mice. These secondary mice showed a continuing
enhanced output of IK6+ cells (Figures S1E and S1F). In
three mice, a serially transplantable and fatal IK6+
(GFP+) T cell leukemia developed. These findings confirm
the expected T-leukemogenic activity of our IK6 vector in
transduced mouse hematopoietic cells and reveal its
ability to enhance normal mouse GM, but not B cell,
production.eports j Vol. 3 j 841–857 j November 11, 2014 j ª2014 The Authors 841
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Figure 1. IKAROS Expression and Inhibition by IK6 in Human CB Cells
(A) Human IKAROS exon structure.
(B) Isoform-specific IKZF1 transcripts determined by qRT-PCR in IK6- and control-transduced CD34+ CB cells and their clonally derived
erythroid (from BFU-E) and GM progeny (from CFC-GM; mean ± SEM; three experiments).
(legend continued on next page)
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IK6 Effects on Primitive Normal Human HSCsTransduction of human CD34+ CB cells consistently
yielded 40% IK6- (GFP+) and control-transduced (YFP+)
cells with a robust and specific increase in IK6 transcripts
in the derived GFP+ cells (Figure 1B). Western blot analysis
confirmed expression of the correct size of IK6 protein at a
3-fold higher level than wild-type IKAROS proteins in the
same cells (Figure 1C). Flow cytometric analyses of unma-
nipulated human CB cells indicated readily detectable
levels of IKAROS protein in CD34+CD38CD45RA
CD90+CD49f+ cells, the most highly enriched hematopoi-
etic stem cell (HSC)-containing CB subset thus far
described (Notta et al., 2011). These levels of IKAROS re-
mained unchanged until they decreased markedly upon
entry into the terminally differentiating neutrophil and
erythroid compartments (Figure 1D). Confocal image ana-
lyses demonstrated the expected punctate nuclear localiza-
tion of IKAROS in normal CB CD34+ cells and its absence
from the nucleus in their IK6-transduced counterparts (Fig-
ure 1E). The aberrant cytoplasmic retention of IKAROS
protein seen in the IK6-transduced CB cells is typical of pri-
mary IK6+ leukemias (Iacobucci et al., 2008; Sun et al.,
1999) and, together with the mouse leukemogenic activity
of our IK6 virus, validates its expected dominant-negative
effects.
IK6 Exerts Species-Specific Effects on Human
Hematopoietic Cells Produced in Transplanted Mice
To examine the effects of IK6 on human hematopoietic
cells, we used a similar cotransplant strategy in which
IK6- and control-transduced CD34+ CB cells were coin-
jected into both NSG mice and NSG mice producing hu-
man interleukin-3 (IL-3), GM colony-stimulating factor
(GM-CSF), and Steel factor (SF) (NGS-3GS mice; Figure 2A).
Measurement of IKZF1 transcripts and intracellular
IKAROS protein levels in different subsets of GFP+ human
CD34+ cells isolated from these mice confirmed their
continuing specific and high-level expression of the IK6
transgene (Figures 2B and 2C).
At 8–10 weeks posttransplant, the BM and spleens of
both types of recipient contained 5- to 10-fold more hu-
man CD45+ cells derived from IK6- (GFP+) as compared to
control-transduced (YFP+) cells (p < 0.01; Figure 2D). How-
ever, the IK6-mediated increase in human cell production
in this system was due to different lineage-specific effects
than those seen with mouse cells. Specifically, in contrast
to the IK6-mediated decrease in mouse B cell outputs
(Figure S1), IK6 caused a 13 ± 3-fold increase in human
B-lineage (CD19+) cell production, without any detectable(C) IKAROS protein isoforms in CD34+ CB cells analyzed by western bl
(D) Representative flow cytometric profiles of intracellular IKAROS in
(E) Confocal microscopy images of representative single untransduced
antibody reactive with both full-length IKAROS and IK6 (red). Scale
Stem Cell Ralteration in their stepwise differentiation (as indicated by
similarly enhanced ratios of IK6- to control-derived human
cells down to the stage of surface immunoglobulin M+ B
cell production; Figures 2E and 2F). Also in contrast to
the transduced mouse cells, IK6 had no detectable effect
on the output of human CD3+ (T) cells, including
CD45RO+ (memory) and CD45RA+ (naive) T cell subsets
(Figures 2F and S2), or human CD3CD56+ (natural killer
[NK]) cells. Nevertheless, the in vivo output of CD33+
(GM) cells from IK6-transduced human CB cells was signif-
icantly enhanced (Figures 2E and 2F), as also seen in the
mouse experiments (Figure S1). Recipients of transduced
human CB cells also showed a decreased number of circu-
lating platelets derived from the IK6-transduced cells as
compared to controls (Figure 2G). The same was the case
for the erythroid (but not the GM) colony-forming cells
(CFCs) in the CD34+CD38+CD45RAFLT3+ cells isolated
from the BMof themice (Figure 2H). These results are of in-
terest, in light of previous data suggesting normal IKAROS
activity is required for mouse and human erythropoiesis
but acts as a negative regulator of mouse megakaryopoiesis
(Dijon et al., 2008; Lopez et al., 2002; Malinge et al., 2013).
Together, these findings show that IK6 has selective,
rapid, and species-specific effects on the outputs of dif-
ferent lineages produced in vivo (in transplanted immuno-
deficient mice) from transduced human CD34+ CB cells.
IK6-Enhances the Long-Term In Vivo Expansion of
Primitive Human Hematopoietic Cells but Is Not
Leukemogenic
In the human CB transplant experiments, we found the
progeny of IK6-transduced cells were more prominent
in all primitive (CD34+) human phenotypes examined
10 weeks posttransplant (including lymphoid- and
myeloid-restricted as well as lymphomyeloid progenitors;
Figure 2I). Secondary transplants of pooled BM cells har-
vested from three of the 10-week primary mice were then
performed (equivalent to one primary mouse, comprising
cells from two femurs, two tibiae, and the pelvis, per sec-
ondary recipient). Ten weeks later, none of these secondary
mice contained detectable progeny of the control-trans-
duced cells (<0.01% YFP+ chimerism). In contrast, GFP+
progeny of the IK6-transduced cells, including CD34+,
GM, B, T, and NK cells, were readily detectable in all three
secondary mice (0.2%–7% BM chimerism).
In a second, similarly designed, human CB transplant
experiment, significantly higher outputs from IK6-trans-
duced cells were maintained for 6 months compared withotting with histone H3 as the loading control.
normal human CB cell subsets (from one of three experiments).
or IK6-transduced CD34+ CB cells stained with DAPI (blue) and an
bar, 10 mm.
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IK6 Effects on Primitive Normal Human HSCscontrols, including a greater content of IK6+ cells in
different CD34+ subsets as well as the B and GM lineages
(Figures 3A and 3B). To assess the regenerative activity
of the more primitive cells, we isolated the human
CD34+CD38 cells from the 6-month primary mice and
transplanted the equivalent of 18% or 90% of the cells pre-
sent in one primarymouse (obtained from two femurs, two
tibiae, and the pelvis) into each secondary mouse. These
secondary recipients again showed a significantly greater
content of IK6+ as compared to control cells another
10 weeks later (Figure 3C), and the proportion engrafted
with human IK6+ cells was also higher (Figure 3D). The
absolute numbers of 10-week human lymphomyeloid re-
populating cells regenerated in the primarymice calculated
from these data revealed a 10-fold higher number of those
derived from the IK6-transduced cells (IK6 = 1.5 versus
control % 0.15, p = 0.0003; Figure 3E). Analysis of the
same secondary mice another 20 weeks later (i.e., 30 weeks
posttransplant) reinforced this difference in the ability of
IK6 to enhance the regeneration in vivo of human cells
with very-long-term multipotent repopulating activity
(Figure 3F). Notably, even after the full 60 weeks of
follow-up through two serial transplants, there was no
evidence of leukemia in any mice.
Together, these studies provide definitive evidence of a
marked stimulatory, but nontransforming, effect of IK6
on the regeneration in vivo of very primitive human he-
matopoietic cells.
IK6 Has Direct and Opposite Effects on Human GM
and Erythropoietic Progenitors
Direct transduction of either early (CD34+CD38) or
late-stage (CD34+CD38+FLT3+CD45RA+/) phenotypically
defined GM progenitors with IK6 did not alter their fre-
quency of GM colony formation in vitro (Figures S3A and
S3B) or the size of clones generated (Figure S3C). InFigure 2. Enhanced Multilineage Repopulating Activity of IK6-Tr
(A) Experimental design.
(B) Ratio of ABL1/B2M normalized IKZF1 transcript levels in transduc
four mice).
(C) Representative flow cytometric profiles of total IKAROS protein in h
control).
(D) Paired comparisons of total IK6- and control-derived human CD
(24 mice from five cohorts).
(E and F) Ten-week posttransplant levels of human CD19+ and surface
mice shown in (D).
(G) Platelet levels in the blood of NSG mice transplanted 4–10 weeks
(H) Colonies derived from equal numbers of IK6- and control-transd
transplanted 10 weeks previously (mean ± SEM; three mice).
(I) Levels of different human CD34+ subsets in the BM of primary NSG
Progenitor-enriched fractions: multipotent, CD34+CD38; lymphoid
granulopoietic, CD34+CD38+CD45RA+FLT3+. BFU-E, burst-forming unit
***p < 0.001. See also Figure S2.
Stem Cell Rcontrast, despite a similar level of expression of IK6 tran-
scripts in the differentiated erythroid and GM cells ulti-
mately obtained, direct transduction of every stage of
erythroid progenitor selectively reduced the clonogenic
activity of the IK6+ cells (Figures S3D and S3E). Although
the erythroid colonies generated from IK6-transduced cells
did not appear obviously altered in size,morphology, or he-
moglobinization, flow cytometric analysis showed they
contained an increased proportion of CD71±GPA (imma-
ture) erythroblasts and a reduced content of CD71GPA+
(more mature) erythroid cells compared to controls (Fig-
ures S3F and S3G). Consistent with these finding was the
reduced expression of two genes critical to erythroid cell
maturation (NFE2 andGATA1) in the IK6-derived erythroid
colonies (Figure S3H).
To examine effects on earlier stages of granulopoiesis, we
compared the output of GM-lineage cells for up to 6 weeks
in long-term cultures (LTCs) (Hogge et al., 1996) modified
to includemouse fibroblasts engineered to produce human
FLT3-ligand (FL) as well as G-CSF, SF, and IL-3 (Figure 4A).
The FL-producing feeders were included because we have
found this improves CFC-GM outputs from primitive sub-
sets of CD34+ CB cells cultured for R6 weeks under these
conditions (M. Liu, A. Cheung, D.J.H.F.K., K. Lucke,
S. Imren, Y. Zhao, V. Lecault, D.E. Hogge, J. Piret, C. Han-
sen, R.K. Humphries, and C.J.E., unpublished data). After
4 weeks, the nonadherent populations in these LTCs con-
sisted almost exclusively of terminally differentiated
monocytes and neutrophils (Figure 4B), with a greater
contribution from the IK6-expressing cells than from the
control-transduced cells (Figure 4C). We also detected a
slightly (but significantly [p < 0.01]) reduced frequency of
nonviable cells in themature (nonadherent) IK6+ cells (Fig-
ure 4D). Fortnightly assessment of the CFC-GM content of
these LTCs showed that 3-fold more were produced from
the IK6-transduced cells, although this increase did notansduced Human CD34+ CB Cells
ed CD34+ human cell subsets generated in NSG mice (mean ± SEM,
uman cells generated in five NSG mice (dotted line shows unstained
45+ cells in individual mice transplanted 8–10 weeks previously
immunoglobulin M+ (B), CD3+ (T), and CD33+ (GM) cells in the same
previously (mean ± SEM; seven mice from two cohorts).
uced myeloerythroid progenitors sorted from the BM of NSG mice
mice transplanted 10 weeks previously (mean ± SEM, 14 mice).
, CD34+CD38+CD10+; myeloerythroid, CD34+CD38+CD45RAFLT3+;
-erythroid; CFC-GM, colony-forming cell-GM. *p < 0.05; **p < 0.01;
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IK6 Effects on Primitive Normal Human HSCsbecome apparent until the sixth week (Figure 4E). By this
time, the total number of IK6-derived CD34+ cells in the
cultures was also 3-fold higher than controls (Figure 4F).
Interestingly, the increase in total cells was preceded by a
small but statistically significant reduction of apoptotic
(cleaved caspase-3+) cells in the IK6-expressing CD34+ pop-
ulation present in 4- to 5-week LTCs (Figure 4G).
To define more precisely which GM progenitors can be
functionally affected by expression of IK6, we examined
the serial output of CFC-GMs in stroma-free growth
factor-supplemented suspension cultures initiated with
different subsets of directly transduced CD34+ CB cells.
Primitive CD34+CD38 (lymphomyeloid-enriched) pro-
genitors produced a late and significant increase in CFC-
GMs (Figure 4H) that was not seen when IK6 was
introduced into the more differentiated CD34+CD38+
CD45RAFLT3+ (myeloerythroid-enriched) progenitors
(Figure 4I), although a transiently increased CFC-GM
output was seen in cultures initiated with the even later
IK6-transduced CD34+CD38+CD45RA+FLT3+ cells (which
consist mainly of CFC-GMs) (Figure 4J).
Together, these findings point to an ability of IK6 to
strongly enhance the generation of primitive human GM
progenitors, with a potential modulation of their survival
but little effect on their subsequent differentiation. This
contrasts with the marked inhibitory effect that IK6 exerts
on human erythropoietic and platelet precursors.
IK6 Sensitizes Human GM Progenitors Selectively to
GM-CSF and IL-3
To investigate mechanism(s) by which IK6-mediated sup-
pression of IKAROS in CB cells may enhance production
of GM progenitors and/or their more primitive precursors,
we examined the 6-week outputs of cells in separate LTCs
containing FL-producing feeders to which IL-3, GM-CSF,
G-CSF, SF, or IL-5 was then added individually as part of
the weekly medium exchange. The addition of either
GM-CSF or IL-3, but not G-CSF, SF, or IL-5, had a marked
enhancing effect on cell outputs from IK6+ cells as
compared to controls (Figure 5A). Flow cytometric analysisFigure 3. IK6 Enhances the In Vivo Expansion of Multipotent Rep
(A) Experimental design.
(B) Different subsets of IK6- and control-derived human cells in th
eight mice).
(C) Levels of human CD19+ (B) and CD33+ (GM) cells derived from IK6-
mice transplanted 10 weeks previously. Limit of detection = 0.0001%
(D) Frequency of secondary mice dually repopulated with control- or
(E) Plot of data shown in (D), generated using the ELDA algorithm
nonengrafted (nonresponding) mice plotted on a linear scale on the
(F) Levels of human CD19+ (B) and CD33+ (GM) cells derived from cont
mice transplanted 30 weeks previously.
*p < 0.05; **p < 0.01; ***p < 0.001.
Stem Cell Rof the cells present in 6-week cultures to which GM-CSF or
IL-3 was added did not show any alteration in GM-CSF or
IL-3 receptor expression on any primitive or mature cell
subpopulation (data not shown). However, CFC-GM assays
of freshly transduced CD34+ cells demonstrated that IK6
expression rendered them more sensitive to either GM-
CSF- or IL-3-stimulated colony formation (Figures 5B and
5C). This occurred in the absence of any evidence of auto-
crine GM-CSF or IL-3 production (based on the absence of
both transcripts by quantitative RT-PCR [qRT-PCR] and
secreted protein by ELISA; data not shown). Thus, the
enhanced GM-cell output from IK6-transduced CD34+ CB
cells appears to be mediated, at least in part, by cell-
intrinsic changes that sensitize their responses to GM-CSF
and IL-3 in ways that do not affect responses to FL, SF,
G-CSF, or IL-5.
Given that IK6-transduced mouse LSKs also showed
enhanced granulopoiesis in vivo, we asked whether this
might also be associated with an increased sensitivity to
IL-3. However, the outputs from IK6- and control-trans-
duced mouse progenitors were equivalent across a wide
range of IL-3 dilutions (Figure S4), indicating a species-
specific effect of IK6 in enhancing the IL-3 sensitivity of
human cells.
IK6 Activates CREB and Its Downstream Targets FOS
and Cyclin B1
Intracellular flow cytometric analysis of mature (CD34
11b+) myeloid cells isolated from LTCs showed that pre-
(basal), and post-GM-CSF- or IL-3-activated levels of
phospho-CREB were higher in the progeny of IK6-trans-
duced cells as compared to controls, although the levels
of phospho-STAT3 and phospho-STAT5 were not consis-
tently different (Figure 5D). A more comprehensive anal-
ysis of CD34+ cells from the same LTCs also showed no
difference in basal JAK-STAT pathway activity in the IK6-
transduced cells but revealed consistently higher basal acti-
vation of several other key signaling elements, including
CREB and members of the RAS pathway (Figure 5E). After
GM-CSF or IL-3 stimulation, peak levels of phosphorylatedopulating Human CB Cells
e BM of primary NSG mice 26 weeks posttransplant (mean ± SEM;
and control transduced cells in the BM of individual secondary NSG
based on analyses ofR106 live cells.
IK6-transduced human lymphoid and myeloid cells.
(Hu and Smyth, 2009), showing the natural log fraction of the
y axis versus the transplant cell dose on the x axis.
rol- and IK6-transduced cells in the BM of individual secondary NSG
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Figure 4. IK6 Enhances GM Outputs at Multiple Stages of GM Progenitor Differentiation
(A) Experimental design.
(B) Numbers of mature cell types in the nonadherent fraction of 4-week-old LTCs (200 cells assessed/sample; three experiments).
(C) Kinetics of the enhancing effect of IK6 on LTC cell outputs (mean ± SEM; three experiments).
(D) Proportion of PI+ nonadherent IK6- and control-transduced cells in 3- to 4-week-old LTCs (mean ± SEM; three experiments).
(E) Total CFC-GMs derived from IK6- and control-transduced cells in LTCs (mean ± SEM; three experiments).
(F) Total CD34+ cells derived from IK6- and control-transduced cells in 6-week LTCs (mean ± SEM; three experiments).
(legend continued on next page)
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IK6 Effects on Primitive Normal Human HSCsCREB were also significantly higher in the CD34+ progeny
of IK6-transduced cells (Figure 5F and data not shown).
This greater activation of CREB was evident over a range
of GM-CSF concentrations (Figure 5G).
Previous studies have linked CREB activation to cell cycle
control (Zhang et al., 2005). To investigate whether IK6
expression was associated with altered expression of cell
cycle regulators, we surveyed a number of candidates.
The results showed FOS, CCNA2 and CCNB1 transcripts
to be significantly higher in subsets of CD34+ cells derived
in vitro (in LTCs) from IK6-transduced cells as compared to
controls (Figure 6A). FOS protein was also significantly
more abundant in CD34+ cells generated in vitro from
IK6-transduced cells with a mean fluorescence intensity
(MFI) value for IK6+ cells of 209 ± 11 versus 175 ± 15 for
controls (p = 0.01; Figure 6B). Extension of these analyses
to primitive subsets generated in xenografted mice again
revealed significantly higher levels of phospho-CREB in
IK6-derived CD34+CD38+CD10 (early myeloid) as well
as CD34+CD38+CD10+ (early lymphoid) cells (Figure 6C).
Intracellular levels of FOS were also higher in the early
myeloid, but not the early lymphoid, cells obtained from
the same mice (Figure 6D). In addition, we found that a
higher proportion of the IK6-derived early myeloid and
lymphoid cells stained positively for Cyclin B1 (Figures
6E and 6F). These findings identify CREB and its targets,
FOS and Cyclin B1, as candidate deregulated mediators of
the effects of IK6 effects in human hematopoietic cells.
IK6 Prematurely Activates a B Cell Transcriptional
Program in Transduced Human CD34+CD38 Cells
Examination of the levels of expression of candidate
IKAROS target genes (Ferreiro´s-Vidal et al., 2013; Ma
et al., 2010; Ross et al., 2012; Zhang et al., 2012) in IK6-
transduced human progenitor subsets isolated from
repopulated mice revealed CCND2 transcripts (encoding
the cell-cycle regulator Cyclin D2) to be elevated in
CD34+CD38+CD10+ (early lymphoid) cells, but not in
other CD34+ subset (Figure 7A). However, we did not detect
any effects on the expression of other genes assessed in
these experiments, which includedMYC and CDKN1B (en-
coding p27). These findings suggest that Cyclin D2 may
play a role in the IK6-induced expansion of human
lymphoid progenitors, but not their multipotent or
myeloid counterparts.
Transcriptome-wide gene expression data were obtained
by analysis of human CD34+CD38 cells sorted from three(G) Proportion of cleaved caspase-3+ CD34+ cells derived from IK6- an
experiments).
(H–J) CFC-GMs in suspension cultures initiated with different subsets
SEM; three experiments).
*p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S3.
Stem Cell Rmice transplanted 10 weeks earlier with transduced CD34+
CB cells. KEGG database interrogation identified 26 upre-
gulated pathways (14%) and nine downregulated path-
ways (5%) in the IK6+ cells as compared to control cells
(threshold: q < 0.1; Table S1). Notably, more than half the
pathways upregulated in the IK6+ cells were related to
signaling or cancer (31% and 23%, respectively). Further
interrogation of this transcriptome data set for possible dif-
ferential enrichment of genes harboring computationally
derived transcription factor binding sites (using TRANSFAC
data sets) identified CREB, STAT5, FOXO, E2F, and LEF1
(threshold: q < 0.1; Table S2). In contrast, results for genes
harboring MYC binding sites were equivocal (Figure 7B). A
more focused analysis using lists of CREB and STAT5 target
genes derived from studies of human cells (Dawson et al.,
2012; Zhang et al., 2005) revealed significantly different
CREB target gene expression in the CD34+CD38 progeny
of the IK6-transduced cells (q = 0.002; Figure 7C) but no dif-
ference in STAT5 target gene expression (q = 0.4).
Expression of genes harboring binding sites for the
lymphoid-specific LEF1 transcription factor were found to
be increased in IK6-derived CD34+CD38 cells (Figure 7B),
suggesting activation of a B-lineage differentiation pro-
gram. To further investigate this possibility, we compared
our data set with a set of genes that were at least 2-fold
more highly expressed in normal human CD34+38+10+
(early B-lineage) cells as compared to human multipotent
(HSC-enriched) CD34+CD38 cells (Hystad et al., 2007).
This comparison demonstrated significant upregulation
of the B-lineage gene set in the IK6+ CD34+CD38 cells as
compared with controls (q = 0.02; Figure 7D). In contrast,
a parallel analysis of these cells for genes normally ex-
pressed at higher levels in human CD34+CD38 cells
than in later progenitors (Eppert et al., 2011; Novershtern
et al., 2011) demonstrated no corresponding IK6-associ-
ated difference (q = 0.6 and q = 0.7). These findings demon-
strate that IK6 initiates a B-lineage transcriptional program
prematurely in CD34+CD38 cells, without compromising
the expression of an HSC transcriptional signature.DISCUSSION
Growing evidence suggests that the mechanisms by which
signaling networks regulate normal human HSC self-
renewal and lineage restriction are highly complex pro-
cesses that involve many genes implicated in humand control-transduced cells in 4- to 5-week LTCs (mean ± SEM; three
of transduced CD34+ CB cells (normalized to 103 input cells; mean ±
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IK6 Effects on Primitive Normal Human HSCsleukemogenesis. Nevertheless, the role in normal human
hematopoiesis played by many of these leukemia-associ-
ated genes remains poorly understood. Much has been
learned from studies of genetically manipulated mouse
cells, inwhich the expression of genes from an endogenous
promoter can be controlled both temporally and in a line-
age-specific manner. However, the conclusions derived
from mouse models are necessarily limited by species-spe-
cific differences (Payne and Crooks, 2007; Rangarajan and
Weinberg, 2003). Fortunately, recent technical advances
are making it increasingly possible to assess the conse-
quences of direct genemanipulation in humanhematopoi-
etic cells. These include the development of lentiviral
vectors that can efficiently transduce primitive human he-
matopoietic cell populations, improved multiparameter
flow cytometry, array-based techniques applicable to small
numbers of cells, and the generation of highly immunode-
ficient long-lived strains of mice that can reproducibly sup-
port sustained, high-level reconstitution with human
hematopoietic cells (Billerbeck et al., 2011; Doulatov
et al., 2012; Miller et al., 2013). Here, we exploited such
methods to examine and compare the cellular andmolecu-
lar consequences of IK6 in primitive normal human and
mouse hematopoietic cells. In addition, we made use of
an experimental design in which matched numbers of
IK6- and control-transduced cells were cotransplanted
into the same recipients or analyzed in the same cultures
to enable a precise and accurate comparison of absolute
(rather than relative) lineage contributions not necessarily
otherwise possible.
The most significant finding in these studies was the 10-
fold enhanced expansion of transplantable HSCs in mice
engrafted with IK6-transduced human CD34+ CB cells.
This was indicated both by the higher numbers of
CD34+CD38 cells regenerated from the IK6-transduced
cells after 6 months in primary recipients and by the func-
tional ability of these cells to reconstitute hematopoiesis in
secondarymice for another 7.5months. To our knowledge,Figure 5. IK6 Sensitizes Human GM Progenitors to GM-CSF and IL
(A) Effect of different human growth factors on 6-week cell outputs
replicates each from two experiments).
(B and C) IL-3 and GM-CSF dose-response relationships for GM colon
(mean ± SEM; two replicates each from two experiments).
(D) Differences in levels of intracellular phosphoproteins in IK6- versu
CSF or IL-3 (mean ± SEM of MFI ratios; six to eight experiments).
(E) Basal levels of intracellular phosphoproteins in IK6- versus contr
experiments).
(F) Representative flow cytometric profiles of phospho-CREB levels
control-transduced cells. Dotted lines show staining in the absence o
(G) Phospho-CREB response of CD34+ cells derived from IK6- and contr
SEM for normalized changes in phospho-CREB MFI values, four experi
MFI, median fluorescence intensity; FL, FLT3-ligand. *p < 0.05; **p <
Stem Cell Rthis effect matches or exceeds any strategy for experimen-
tally expanding human HSCs thus far reported. It also
stands in sharp contrast to the reported suppression of
mouse HSC expansion by disruption of IKAROS activity
(Nichogiannopoulou et al., 1999; Papathanasiou et al.,
2009), thus underscoring the importance of using primary
human hematopoietic cells to interrogate the role of
IKAROS in their normal regulation.
Also striking was the consistent IK6-induced in vivo
enhancement of human B-lineage cell generation, in
contrast to the impaired B cell outputs obtained by loss of
IKAROS activity in mouse cells (Joshi et al., 2014; Schwick-
ert et al., 2014) also confirmed here. These effects of IK6 on
human B cell development were presaged by the premature
activation of a B-lineage transcriptional program in the hu-
man HSC-enriched CD34+CD38 compartment, which
did not interfere with their HSC activity or subsequent
execution of normal B cell differentiation. We also saw
different effects on mouse and human T cell outputs,
which were enhanced by IK6 expression in mouse cells,
consistent with previous reports, whereas human T cell
outputs were unaffected. Historical limitations inherent
to previous human modeling systems may explain why
we did not observe the IK6-induced suppression of human
B cell production previously reported in engrafted NOD/
SCID mice (Tonnelle et al., 2001).
One potential explanation for the difference in effects of
IK6 on mouse and human lymphopoiesis could be species-
specific differences in the downstream events activated, as
exemplified by the discrepancies in B cell phenotypes of
human inherited immunodeficiency syndromes when
compared with their equivalent mouse models (Conley
et al., 2000;Mestas andHughes, 2004). Dominant-negative
isoformsmay also differentially suppress wild-type IKAROS
activity in the different models thus far described, raising
the interesting possibility that the antiproliferative and
pro-B-lineage differentiation roles of IKAROS may not be
tightly linked.-3
from IK6- and control-transduced human cells (mean ± SEM; four
y formation from IK6- and control-transduced human CD34+ cells
s control-derived CD3411b+ GM cells stimulated (or not) with GM-
ol-derived CD34+ cells (mean ± SEM of MFI ratios from six to eight
(solid lines) in IL-3-stimulated CD34+ cells derived from IK6- and
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Figure 6. IK6 Activates CREB and Its Targets FOS and Cyclin B1 in CD34+ Human CB Cells
(A) IK6-stimulated gene expression in subsets of CD34+ cells from 3- to 4-week LTCs (mean ± SEM ratio of normalized transcript levels;
seven experiments).
(B) Representative flow cytometric profile of intracellular FOS protein levels (solid lines) in CD34+ cells derived from IK6- and control-
transduced cells in 3-week LTCs. Dotted lines indicate staining in the absence of anti-FOS antibody.
(C) Percentage differences in phosphoprotein levels (MFIs) in different subsets of CD34+ cells generated from IK6- and control-transduced
cells cotransplanted into NSG mice (mean ± SEM, four mice). Phospho-ERK was not detected.
(D) FOS protein levels in progeny of IK6- and control-transduced cells cotransplanted into NSG mice 10 weeks previously (mean ± SEM,
four mice).
(legend continued on next page)
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Figure 7. IK6 Activates a B-Lineage Transcriptional Program Prematurely in Human CD34+CD38 Cells
(A) Normalized transcript levels in subsets of human cells generated from IK6- versus control-transduced cells in four cotransplanted NSG
mice (mean ± SEM).
(B) Differential enrichment of genes bearing specific transcription factor binding sites in a comparison of gene expression data from the
CD34+CD38 progeny of IK6- and control-transduced cells sorted from transplanted mice. ‘‘Up’’ indicates a positive enrichment. ‘‘Down’’
indicates a negative enrichment. ‘‘Mixed’’ indicates enrichment including both up- and downregulated genes.
(C) Unsupervised clustering and heatmap of human CREB target genes (500 genes showing strongest CREB binding in a chromatin
immunoprecipitation sequencing study of human cells; Zhang et al., 2005) showing relative expression (Z score) in CD34+CD38 cells.
(D) Unsupervised clustering and heatmap of 127 genes whose expression is R2-fold higher in normal human CD34+CD38+CD10+ B cell
progenitors as compared to normal human CD34+CD38 CB cells (Hystad et al., 2007) showing their relative expression (Z score) in
CD34+CD38 cells.
*p < 0.05.
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expression on human cells could be traced to several spe-
cific stages of GM progenitors and was associated with a
selectively increased sensitivity to two granulopoietic
growth factors, IL-3 and GM-CSF. These cytokines share a(E) Representative flow cytometric plots of lymphoid progenitor (CD
viously with IK6- and control-transduced cells and then stained for i
(F) Percent Cyclin B1+ human cells in NSG mice cotransplanted with I
four mice).
MFI, median fluorescent intensity; *p < 0.05.
Stem Cell Rcommon signaling receptor component and hence activate
many common downstream intermediates (Gubina et al.,
2001). Hyperactivation of the transcription factor CREB,
and its downstream targets FOS and Cyclin B1, was also
revealed, consistent with a role of IKAROS in normally34+CD38+CD10+) cells from NSG mice cotransplanted 10 weeks pre-
ntracellular Cyclin B1 protein.
K6- and control-transduced cells 10 weeks previously (mean ± SEM;
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poietic cells. In agreement with previous findings (Dijon
et al., 2008), an opposite effect on erythropoietic cells
was noted.
In summary, we provide multiple lines of evidence for a
stimulatory role of IK6 in primitive normal human he-
matopoietic cells, associated with an enhanced activation
of certain signaling intermediates involved in GM-CSF
and IL-3 responses. This finding, reinforced by the demon-
stration of IKAROS protein expression in all known stages
of primitive human hematopoietic cells, strongly impli-
cates IKAROS as a cell-intrinsic negative regulator of HSCs
and their immediate progeny in humans. However, none
of these sequelae appear sufficient to lead to the induction
of leukemia in human cells, suggesting that mutations
targeting IKZF1 require additional alterations in order to
produce such an outcome.EXPERIMENTAL PROCEDURES
Lentiviral Constructs
Human IK6 cDNA was cloned into a pCCL.PPT.MNDU3.PGK.GFP
lentiviral vector (Carbonaro et al., 2006; Challita et al., 1995) and
sequence verified. IK6-GFP and control (empty)-YFP lentivirus was
produced and concentrated as described previously (Imren et al.,
2004). Titration on HeLa cells gave titers of 107 infectious
units/ml.
Mouse Transplantations
C57BL/6J -Ly5.2 (B6) mice were used as donors and congenic B6-
W41/W41-Ly5.1 mice (given 400 cGy) or allogeneic NSG or NSG-
3GS mice (given 315 cGy) were used as recipients. All mice were
bred and maintained in the BC Cancer Research Animal Resource
Centre under specific-pathogen-free conditions in accordance
with Canadian Council on Animal Care guidelines and with
approval from the Animal Care Committee of the University of
British Columbia. LSK BM cells were transduced for 4 hr as
described previously (Copley et al., 2013) (see Supplemental Exper-
imental Procedures) and equal numbers of control and IK6-virus-
exposed cells then immediately coinjected intravenously into
recipients (1.5 3 104 cells each/mouse). For secondary transplants
of mouse cells, pooled BM cells from both femurs and tibiae and
the pelvis of each primary recipient were injected intravenously
into two secondary mice and blood chimerism ascertained as
described previously (Copley et al., 2013).
Human Cells
CD34+ cell-enriched CB populations (>85% pure) were isolated by
EasySep (STEMCELL Technologies) and transduced as previously
described previously (Imren et al., 2004) using a 16 hr presti-
mulation and 8 hr virus exposure protocol (see Supplemental
Experimental Procedures). For xenografts, primary mice were
cotransplanted with equal aliquots of 1–5 3 105 control- and
IK6-transduced cells without further selection. For secondary
transplants, pooled BM cells from both femurs, tibiae and the854 Stem Cell Reports j Vol. 3 j 841–857 j November 11, 2014 j ª2014 Thepelvis of each primary recipient were injected intravenously into
one or more secondary mice with or without prior selection by
fluorescence-activated cell sorting (FACS) of human CD34+CD38
cells, as indicated. Analysis of chimerism was performed as
previously described (Cheung et al., 2012); unstained GFP+ and
YFP+ cells from the same mice were used as negative (unstained)
controls. For in vitro experiments, cells were cultured for 40 hr
posttransduction prior to selection of GFP/YFP+ cells by FACS. All
procedures were carried according to protocols approved by the
University of British Columbia research ethics board.
Western Blotting
Transduced (GFP+ and YFP+) CD34+ CB cells were isolated by FACS
48 hr after viral exposure, lysed, resolved on a 4%–12% Bis-Tris
(SDS) polyacrylamide gel, and transferred to Immobilon-P Transfer
Membrane (Millipore), then immunoblotted with rabbit anti-
IKAROS and histone H3 antibodies (Cell Signaling Technologies).
Proteins were detected by horseradish peroxidase-conjugated
anti-rabbit antibody (Santa Cruz Biotechnology) and Supersignal
FemtoMaximumSensitivity Reagent (Pierce Biotechnology). Non-
saturating signals were acquired using a VersaDoc system (Bio-Rad)
and quantitated using ImageLab version 3 (Bio-Rad).
Confocal Imaging
Transduced CD34+ CB cells were prepared as for intracellular flow
cytometry then cytospun onto coated slides. Slides were mounted
with Vectashield containing DAPI (VECTOR Laboratories). Images
were acquiredwith a FluoView confocal laser scanningmicroscope
(Fv10i, Olympus) and processed with ImageJ.
Intracellular Flow Cytometric Analyses
See Supplemental Experimental Procedures for details regarding
intracellular flow cytometric analyses.
Cell Cultures
CFC assays and LTCs were performed as described previously
(Hogge et al., 1996), using for the LTCs a mixture of irradiated
M210B4 and Sl/Sl mouse stromal cells producing human SF, IL-3,
FL, andG-CSF. Live (propidium iodide negative [PI]) nonadherent
cells were enumerated by flow cytometry using fluorescent count-
ing beads (AccuCheck, Life Technologies) and their morphology
determined on Wright-Giemsa-stained cytospin preparations.
For suspension culture experiments, test cells were incubated in
either serum-free medium (SFM) with growth factors (as for lenti-
viral exposure; Figures 4H–4J) or H5100 media with GM-CSF
(Figure S3C).
To compare the cytokine sensitivity of IK6- and control-trans-
duced lineage-SCA-1+CD3 B6 mouse BM cells, 104 of each were
cocultured in 100 ml SFM in 96-well plates with added mouse SF
or IL-3, as indicated. After 4 days, total viable (PI) GFP+ and
YFP+ cells in each well were enumerated by flow cytometry using
fluorescent counting beads.
qRT-PCR
RNAwas prepared using spin columns (QIAGEN) and cDNA using
SuperScript VILO (Life Technologies). Primers for qRT-PCR wereAuthors
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IK6 Effects on Primitive Normal Human HSCsdesigned to amplify across at least one intron and produce a
product of 80–100 bp using Primer3 software (http://frodo.wi.
mit.edu/). qRT-PCR reactions were performed using Fast SYBR
green (Life Technologies) and a 7500 Fast Real-Time PCR analyzer
(Applied Biosystems). Transcripts were normalized to ABL1 and/or
B2M as indicated and the mean DCt values used to generate ratios
of transcript levels in IK6 versus control cells.Statistical Analysis
IK6 and control-transduced cell outputs were compared using the
Student’s t test (paired or unpaired as appropriate). IL-3 and GM-
CSF surface receptor expression was compared by unbiased anal-
ysis of flow cytometry data using the flowType and RchyOptimyx
algorithms (Aghaeepour et al., 2012a; Aghaeepour et al., 2012b).Gene Expression Analysis
See Supplemental Experimental Procedures for details regarding
gene expression analysis.
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